Vaccination of Renal Cell Cancer Patients With Modified Vaccinia Ankara Delivering the Tumor Antigen 5T4 (TroVax) Alone or Administered in Combination With Interferon-α (IFN-α) A Phase 2 Trial

被引:60
作者
Amato, Robert J. [1 ]
Shingler, William [3 ]
Goonewardena, Madusha [3 ]
de Belin, Jackie [3 ]
Naylor, Stuart [3 ]
Jac, Jaroslaw [2 ]
Willis, James [2 ]
Saxena, Somyata [2 ]
Hernandez-McClain, Joan [1 ]
Harrop, Richard [3 ]
机构
[1] Univ Texas Hlth Sci Ctr, Mem Hermann Canc Ctr, Houston, TX 77030 USA
[2] Methodist Hosp, Res Inst, Texas Med Ctr, Houston, TX 77030 USA
[3] Oxford BioMed UK Ltd, Medawar Ctr, Oxford, England
关键词
genitourinary cancers; other; phase; 1-3; trials; clinical immunology; cancer vaccines; laboratory correlates; ONCOFETAL ANTIGEN; CARCINOMA; INTERLEUKIN-2; EXPRESSION;
D O I
10.1097/CJI.0b013e3181ace876
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Attenuated vaccinia virus, modified vaccinia Ankara (MVA) has been engineered to deliver the tumor antigen 5T4 (TroVax). MVA-5T4 has been evaluated in an open-label phase 2 trial in metastatic renal cell cancer patients in which the vaccine was administered alone or in combination with interferon-alpha-2b (IFN-alpha). The safety, immunologic and clinical efficacy of MVA-5T4 with or without IFN-alpha was determined. Twenty-eight patients with metastatic renal cell cancer were treated with MVA-5T4 alone (13) or plus IFN-alpha (15). The 5T4-specific cellular and humoral responses were monitored throughout the Study. Clinical responses were assessed by measuring changes in tumor burden by computed tomography or magnetic resonance imaging scan. MVA-5T4 was well tolerated with 110 Serious adverse event attributed to vaccination. Of 23 intent-to-treat patients tested for immune responses postvaccination, 22 (96%) mounted 5T4-specific antibody and/or cellular responses. One patient treated with MVA-5T4 plus IFN-alpha showed a partial response for > 7 months, whereas an additional 14 patients (7 receiving MVA-5T4 Plus IFN and 7 receiving MVA-5T4 alone) showed periods of disease stabilization ranging from 1.73 to 9.60 months. Median progression free survival and overall survival for all intent-to-treat patients was 3.8 months (range: 1 to 11.47mo) and 12.1 months (range: 1 to 27 mo), respectively. MVA-5T4 administered alone or in combination with IFN-alpha was well tolerated in all patients. Despite the high frequency of 5T4-speciric immune responses, it is not possible to conclude that patients are receiving clinical benefit. The results are encouraging and warrant further investigation.
引用
收藏
页码:765 / 772
页数:8
相关论文
共 17 条
  • [1] *AM CANC SOC, 2006, CANC FACTS FIG 2006
  • [2] Vaccination of Renal Cell Cancer Patients with Modified Vaccinia Ankara Delivering Tumor Antigen 5T4 (TroVax) Administered with Interleukin 2: A Phase II Trial
    Amato, Robert J.
    Shingler, William
    Naylor, Stuart
    Jac, Jaroslaw
    Willis, James
    Saxena, Somyata
    Hernandez-McClain, Joan
    Harrop, Richard
    [J]. CLINICAL CANCER RESEARCH, 2008, 14 (22) : 7504 - 7510
  • [3] Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) - A phase 2 trial
    Amato, Robert J.
    Drury, Noel
    Naylor, Stuart
    Jac, Jaroslaw
    Saxena, Somya
    Cao, Amy
    Hernandez-McClain, Joan
    Harrop, Richard
    [J]. JOURNAL OF IMMUNOTHERAPY, 2008, 31 (06) : 577 - 585
  • [4] [Anonymous], NCI COMMON TOXICITY
  • [5] Sarcomatoid renal cell carcinoma: Biologic behavior, prognosis, and response to combined surgical resection and immunotherapy
    Cangiano, T
    Liao, J
    Naitoh, J
    Dorey, F
    Figlin, R
    Belldegrun, A
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (02) : 523 - 528
  • [6] Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: a potential target for T-cell-based immunotherapy
    Griffiths, RW
    Gilham, DE
    Dangoor, A
    Ramani, V
    Clarke, NW
    Stern, PL
    Hawkins, RE
    [J]. BRITISH JOURNAL OF CANCER, 2005, 93 (06) : 670 - 677
  • [7] Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated
    Harrop, R
    Ryan, MG
    Myers, KA
    Redchenko, I
    Kingsman, SM
    Carroll, MW
    [J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2006, 55 (09) : 1081 - 1090
  • [8] Vaccination of colorectal cancer patients with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses
    Harrop, Richard
    Drury, Noel
    Shingler, William
    Chikoti, Priscilla
    Redchenko, Irina
    Carroll, Miles W.
    Kingsman, Susan M.
    Naylor, Stuart
    Melcher, Alan
    Nicholls, Joanna
    Wassan, Harpreet
    Habib, Nagy
    Anthoney, Alan
    [J]. CLINICAL CANCER RESEARCH, 2007, 13 (15) : 4487 - 4494
  • [9] Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A phase I/II trial
    Harrop, Richard
    Connolly, Noel
    Redchenko, Irina
    Valle, Juan
    Saunders, Mark
    Ryan, Matthew G.
    Myers, Kevin A.
    Drury, Noel
    Kingsman, Susan M.
    Hawkins, Robert E.
    Carroll, Miles W.
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (11) : 3416 - 3424
  • [10] Vaccination of Patients With Metastatic Renal Cancer With Modified Vaccinia Ankara Encoding the Tumor Antigen 5T4 (TroVax) Given Alongside Interferon-α
    Hawkins, Robert E.
    Macdermott, Catriona
    Shablak, Alaaeldin
    Hamer, Caroline
    Thistlethwaite, Fiona
    Drury, Noel L.
    Chikoti, Priscilla
    Shingler, William
    Naylor, Stuart
    Harrop, Richard
    [J]. JOURNAL OF IMMUNOTHERAPY, 2009, 32 (04) : 424 - 429